Tags

Type your tag names separated by a space and hit enter

[Neuraminidase inhibitors in therapy of influenza].
Acta Med Austriaca. 2000; 27(5):133-40.AM

Abstract

Neuraminidase promotes influenza virus release from infected cells and facilitates virus spread within the respiratory tract. Several specific inhibitors of these enzyme have been developed. Zanamivir and oseltamivir are the nowadays available neuraminidase inhibitors. In contrast to amantadine and rimantadine, which target the M2 protein of influenza A, they inhibit the replication of both influenza A and B. Zanamivir is delivered by inhalation because of its low oral bioavailability. Oseltamivir can be administered orally. Early treatment reduces the severity and duration of illness and associated complications. These drugs are not effective at afebrile, mild courses, or if the influenza symptoms have existed already for more than 2 days. They are not effective against other respiratory viruses. For an optimal usage of the neuraminidase inhibitors a rapid and reliable diagnosis is necessary. The clinical diagnosis is sufficient only in proven epidemics. An increased availability of sensitive and specifically diagnostical tests is necessary for individual therapy decisions. The influenza vaccination is the most effective measure against influenza.

Authors+Show Affiliations

Abteilung für Infektiologie der Medizinischen Universitätsklinik, Graz.No affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article
Review

Language

ger

PubMed ID

11261262

Citation

Fladerer, P, and C Wenisch. "[Neuraminidase Inhibitors in Therapy of Influenza]." Acta Medica Austriaca, vol. 27, no. 5, 2000, pp. 133-40.
Fladerer P, Wenisch C. [Neuraminidase inhibitors in therapy of influenza]. Acta Med Austriaca. 2000;27(5):133-40.
Fladerer, P., & Wenisch, C. (2000). [Neuraminidase inhibitors in therapy of influenza]. Acta Medica Austriaca, 27(5), 133-40.
Fladerer P, Wenisch C. [Neuraminidase Inhibitors in Therapy of Influenza]. Acta Med Austriaca. 2000;27(5):133-40. PubMed PMID: 11261262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Neuraminidase inhibitors in therapy of influenza]. AU - Fladerer,P, AU - Wenisch,C, PY - 2001/3/23/pubmed PY - 2001/5/1/medline PY - 2001/3/23/entrez SP - 133 EP - 40 JF - Acta medica Austriaca JO - Acta Med. Austriaca VL - 27 IS - 5 N2 - Neuraminidase promotes influenza virus release from infected cells and facilitates virus spread within the respiratory tract. Several specific inhibitors of these enzyme have been developed. Zanamivir and oseltamivir are the nowadays available neuraminidase inhibitors. In contrast to amantadine and rimantadine, which target the M2 protein of influenza A, they inhibit the replication of both influenza A and B. Zanamivir is delivered by inhalation because of its low oral bioavailability. Oseltamivir can be administered orally. Early treatment reduces the severity and duration of illness and associated complications. These drugs are not effective at afebrile, mild courses, or if the influenza symptoms have existed already for more than 2 days. They are not effective against other respiratory viruses. For an optimal usage of the neuraminidase inhibitors a rapid and reliable diagnosis is necessary. The clinical diagnosis is sufficient only in proven epidemics. An increased availability of sensitive and specifically diagnostical tests is necessary for individual therapy decisions. The influenza vaccination is the most effective measure against influenza. SN - 0303-8173 UR - https://www.unboundmedicine.com/medline/citation/11261262/[Neuraminidase_inhibitors_in_therapy_of_influenza]_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0303-8173&date=2000&volume=27&issue=5&spage=133 DB - PRIME DP - Unbound Medicine ER -